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Abstract
The purpose of this study was to directly (head-to-head)
compare the per-lesion diagnostic performance of con-
trast-enhanced computed tomography (CT) (also re-
ferred to as CT hereafter) and gadoxetic acid disodium
(Gd-EOB-DTPA)-enhanced magnetic resonance (MR)
imaging (also referred to as MRI hereafter) for the
detection of hepatocellular carcinoma (HCC). Studies
reporting direct per-lesion comparison data of contrast-
enhanced multidetector CT and Gd-EOB-DTPA-en-
hanced MR imaging that were published between Jan-
uary 2000 and January 2015 were analyzed. The data of
each study were extracted. Systematic review, paired
meta-analysis, and subgroup analysis were performed.
Twelve studies including 627 patients and 793 HCC le-
sions were analyzed. The sensitivity estimates of MRI
and CT were, respectively, 0.86 (95% CI 0.76–0.93) and
0.70 (95% CI 0.58–0.80), with signiﬁcant difference
(P < 0.05). The sensitivity estimates were both 0.94
(95% CI 0.92–0.96) (Chi-square 4.84, degrees of free-
dom = 1, P > 0.05). In all subgroups, Gd-EOB-DTPA-
enhanced MR imaging was more sensitive than multi-
detector CT for the detection of HCC, and specificity
estimates of both tests maintained at a similarly high
level in all conditions: sensitivity estimates of both tests
were reduced in studies where patients were diagnosed
with HCC solely by liver explant or in those where HCC
lesions were small (£2 cm, especially when £1 cm). But in
all situations, sensitivities of MRI were higher than those
of CT with or without significance. Gd-EOB-DTPA-
enhanced MR imaging showed better per-lesion diag-
nostic performance than multidetector CT for the diag-






Hepatocellular carcinoma (HCC) is the second most
common cause of cancer-related death worldwide. The
estimated 782,000 new cases of HCC were diagnosed in
2012, of which 83% occurred in less developed areas [1].
Only patients with early-stage HCCs can undergo cura-
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tive treatment, including liver resection, liver transplan-
tation, and percutaneous local ablative treatment,
according to the Barcelona Clinic Liver Cancer staging
system [2]. Therefore, the accurate diagnosis of HCC is
important to provide better treatment options for pa-
tients, especially in early-stage HCCs.
Effective non-invasive imaging techniques, including
computed tomography (CT) and magnetic resonance
(MR) imaging, can be used to diagnose HCC. According
to the guidelines of the American Association for the
Study of Liver Diseases (AASLD), a single dynamic
technique showing intense arterial uptake followed by a
‘‘washout’’ of contrast in the venous-delayed phases is
valid to diagnose HCC [3]. These guidelines have been
adopted by the European Association for the Study of
the Liver (EASL) and the European Organization for
Research and Treatment of Cancer (EORTC) [4].
Because of its short acquisition time and high spatial
resolution, CT is commonly used imaging technique for
diagnosing HCC. However, MR imaging, which offers
several beneﬁcial characteristics such as the combination
of various sequences and absence of X-ray radiation, is
also often used independently or in combination with CT
to improve the detection and diagnosis of HCC.
Despite research efforts aimed at identifying the
optimal imaging technique, studies have shown a similar
or slightly better diagnostic performance of dynamic MR
imaging compared with multiphasic CT [5].
In recent years, the introduction of a new MR
imaging contrast agent, gadolinium ethoxybenzyl
diethylenetriamine pentaacetic acid (gadoxetic acid dis-
odium or Gd-EOB-DTPA), may provide a solution. As a
liver-speciﬁc contrast agent, it provides routine multi-
phasic information as well as tissue-speciﬁc physiological
information during the hepatobiliary phase (HBP), thus
improving the detection of HCC [6]. Several studies have
compared the efficacy of Gd-EOB-DTPA-enhanced MR
imaging (also referred to as MRI hereafter) to that of CT
for the detection of HCC. Some studies suggested that
Gd-EOB-DTPA-enhanced MR imaging shows better
diagnostic performance than CT for HCC [7–11],
whereas other studies suggested that there are no sig-
nificant differences between the two techniques [12–16].
There is currently no consensus on the optimal method
for the diagnosis of HCC, and to date, no meta-analysis
has been conducted to clarify this issue.
In the present study, we performed ameta-analysis that
included 12 studies selected according to strict criteria to
estimate and compare the accuracy of Gd-EOB-DTPA-
enhanced MR imaging to that of multidetector CT (also
referred to as CT hereafter) for the diagnosis of HCC.
Materials and methods
This meta-analysis was performed in accordance with the
recommendations outlined in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses state-
ment (PRISMA) [17]. There is no review protocol reg-
istered for this research.
Literature search
The MEDLINE, EMBASE, and Web of Science data-
bases, and the Cochrane Library were searched for studies
analyzing the per-lesion diagnostic accuracy of multide-
tectorCTandGd-EOB-DTPA-enhancedMR imaging for
HCC in patients older than 18 years. The reference lists of
the included original articles were manually checked to
identify additional potential studies. Review articles and
websites of major conferences were also searched. Table 1
shows the detailed search strategy and query terms.
Inclusion and exclusion criteria
Inclusion and exclusion criteria were based on the par-
ticipants, interventions, comparisons, outcomes, and
study design. Studies were included if all of the following
criteria were met: (a) the study was performed for per-
lesion comparison; (b) patients were suspected of HCC
based on prior ultrasound examination or alpha-feto-
Table 1. Literature search strategy
Step no. Query
#1 (Liver OR hepatocellular) OR hepatic
#2 (Carcinoma OR tumor) OR cancer
#3 MeSHa descriptor Carcinoma, Hepatocellular explode all trees
#4 ‘‘Computed tomography’’ OR ‘‘CT’’
#5 MeSH descriptor Tomography, X-Ray Computed explode all trees
#6 ‘‘Magnetic resonance’’ OR ‘‘MR’’
#7 MeSH descriptor Magnetic Resonance Imaging explode all trees
#8 (((‘‘Gd-EOB-DTPA’’ OR ‘‘Gadolinium-EOB-DTPA’’) OR ‘‘gadoxetic acid disodium’’) OR eovist) OR primovist
#9 MeSH descriptor Gadoxetic Acid Disodium explode all trees
#10 (#1 AND #2) OR #3
#11 (#4 OR #5) AND (#6 OR #7)
#12 #8 OR #9
#13 #10 AND #11 AND #12 from January 2000 to January 2015
This table provides details on how the literature was searched in various databases
a Medical subject headings
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protein, or diagnosed with HCC retrospectively; (c)
sample size larger than ten patients; (d) diagnostic results
of true positive (TP), false positive (FP), false negative
(FN), and true negative (TN) were available; (e) both CT
and MR imaging were performed by multiphasic con-
trast-enhanced imaging with Gd-EOB-DTPA as one of
the contrast agents for MR imaging; (f) a CT detector
row of at least four and an MR imaging magnetic ﬁeld
strength > 1.0T; and (g) reference standards were based
on histopathology (explanted liver, liver resection,
biopsy) and/or a clinical follow-up of at least 6 months.
Studies were excluded if (a) any one of the inclusion
criteria was not met; (b) multiple reports were published
for the same study population, in which case only the
most detailed and/or most recent publication was in-
cluded. Discrepancies were resolved through discussion;
and (c) articles published only as conference abstracts
that did not include complete data or non-English lan-
guage papers were not considered.
Literature screening
Two reviewers independently screened the titles and ab-
stracts and assessed the full text to identify potentially
eligible papers. Papers were selected for review if they
included patients with HCC who underwent both mul-
tidetector CT and Gd-EOB-DTPA-enhanced MR
imaging for lesion evaluation.
Quality assessment and data extraction
The quality assessment of diagnostic accuracy studies-2
(QUADAS-2) tool was used to evaluate the quality of all
studies. The quality of primary diagnostic studies was
assessed through estimation of risk of bias for four do-
mains and clinical applicability for three domains of the
study characteristics [18].
Meanwhile, a standardized excel form was used to
extract relevant data from all studies, including author,
year of publication, journal name, country of origin, type
of study design (retrospective or prospective), clinical
characteristics (age, gender, etiology of underlying
chronic liver disease, proportions of cirrhosis, and Child-
Pugh class), sample size (number of patients and number
of HCC lesions), HCC lesion characteristics [lesion size,
degree of tumor differentiation (well/moderately/poor),
vascularity], reference standards, CT and MR imaging
scanner type, number of CT rows, magnetic ﬁeld strength
of MR imaging, timing of arterial/venous/delayed phase
imaging, descriptions of the interpretations of the diag-
nostic tests, interval between imaging readings of both
index texts, imaging interpretation method (blinded or
not, use of a conﬁdence rating scale), and interval be-
tween pathology and imaging scanning. These data are
presented in Table 2.
Values from each study were also extracted including
categories of true positive, false positive, false negative,
and true negative (Table 2). These values were used to
generate a two-by-two contingency table showing the
cross classification of disease status (result of the refer-
ence standard) and test outcome (result of the index test).
Other statistical indexes, including positive likelihood
ratio (PLR) and negative likelihood ratio (NLR), were
also recorded if available. If there were more than two
imaging evaluators, accuracy data were averaged among
them (most of the researches provided the reading results
of more than one image reader. In our work, in order to
count the result in each study, these results of each reader
in one study were average to stand for the results of one
study). For studies including multiple technical aspects
of the same imaging modality, data on the most ad-
vanced technique were extracted from the contingency
table (e.g., data on MR imaging scanning with HBP
combined with routine multiple phases were extracted
instead of data on routine multiple phases alone).
Statistical analysis
Forest plots of sensitivity and speciﬁcity were con-
structed using Review Manager (RevMan) (Version 5.3.
Copenhagen: The Nordic Cochrane Centre, The Co-
chrane Collaboration, 2014). Parameters of bivariate
model were externally calculated (see following) and
were input to deﬁne the SROC curve. These plots were
used to visually explore between-study variation in the
diagnostic accuracy of each test.
We used the xtmelogit command in Stata version 13.0
for Mac (64-bit Intel) (Stata, College Station, TX) to ﬁt
the bivariate model to derive summary estimates of
sensitivity, speciﬁcity, PLR, NLR, and their 95% Con-
ﬁdence Intervals (CIs). The paired sensitivity/speciﬁcity
data for the tests were at level one of the analysis, and a
binary covariate was created to identify each test in the
two-by-two contingency table which had been generated
from data extraction of each study. This model assumed
that the sensitivities/speciﬁes from individual studies
(after logit transformation) are approximately normally
distributed around a mean value with a certain amount
of variability around this mean. It ﬁrst transformed tp/
tn/fp/fn into logit form with corresponding variance, and
then using this logit form and its variance, the sensitivity,
speciﬁcity, and their CIs can be calculated by Wald Chi-
square test. Tests were compared by adding a covariate
for test type to the bivariate model. Likelihood ratio tests
were used to obtain the statistical differences between the
sensitivities and speciﬁcities of the two tests by ﬁtting
alternative models (adding or removing covariate terms
from the model). Subgroup analysis was performed in
the following the same method [19].
Subgroup analysis was pre-speciﬁed to consider
potential factors that could contribute to heterogeneity.
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Those factors included type of study design (prospective
or retrospective), cirrhosis in patients (‘‘cirrhosis’’: all
patients with cirrhosis; ‘‘cirrhosis or not’’: part of pa-
tients with cirrhosis), mean size of HCC lesions, and
reference standards (ﬁndings in explanted liver as the
only reference or not). Meta-regression assists the deci-
sion making in subgroup analysis by revealing the most
signiﬁcant factors for heterogeneity. Therefore, subgroup
analysis was then performed based on the identiﬁed
factors. The ﬁrst level of subgroup analysis was per-
formed by comparing two groups divided by the fact that
whether ﬁndings in liver explantation were used as the
sole reference standard. Three of the studies used ﬁnd-
ings in the liver explantation as the sole reference stan-
dard [11, 14, 16], and the other nine studies had a
composite standard of reference. The second level of
subgroup analysis was performed in the subgroup of nine
studies using a composite reference standard, by com-
paring five studies [7, 10, 13, 20, 21] which enrolled only
patients with liver cirrhosis and those in which not all
patients had liver cirrhosis.
Because lesion size is a substantial factor for the
imaging diagnosis of HCC, subgroup analysis was
independently performed according to lesion size,
regardless of the meta-regression result. In this analysis,
only sensitivity estimates were calculated because of the
lack of true-negative values. We used 1 cm and 2 cm as
cutoff values and compared the diagnostic sensitivities of
the two imaging techniques. In this way, we had four
subgroups of patients data separated extracted from
studies: group 1 where lesions were equal or smaller than
1 cm, group 2 where lesions were larger than 1 cm, group
3 where lesions were equal or smaller than 2 cm, and
group 2 where lesions were larger than 2 cm.
Results
Selection of studies
Multiple database searches initially yielded 568 potential
literature citations, of which 67 were potentially relevant
according to their titles and/or abstracts. Of these, 45
articles were selected for full-text review. Full-paper re-
view excluded 33 articles, and 12 studies were ﬁnally
included in the current meta-analysis. Figure 1 shows the
details of the study selection process.
Study characteristics
The important characteristics of the studies are presented
in Table 2. All studies provided information on a per-
lesion basis. All studies together included 627 patients
with 793 HCC lesions. Most of the studies were retro-
spective, with three claiming to be prospective. Three
studies [11, 14, 16] assessed HCC in patients before liver
transplantation, whereas most of the studies included
patients suspected of HCC or retrospectively diagnosed
with focal liver lesions (FLLs). Eight studies [7, 10, 11,
13, 14, 16, 20, 21] included only patients with cirrhosis.
The average lesion size in all studies was approximately
1.6 cm (range, 0.2–15.2 cm). Five studies used only a 64-
row CT scanner [7, 11, 12, 14, 16]. Two studies used a 16-
row CT scanner [8, 9]. The rest of the studies used a mix
of several CT scanners with row numbers ranging from 6
to 64. For MR imaging, six studies used a 3.0-T scanner
[10, 11, 13, 15, 16, 21] and six used a 1.5-T scanner [7–9,
12, 14, 20]. Seven studies used a reference standard based
solely on histopathology obtained from biopsy, liver
resection, or liver transplantation [8, 9, 11, 12, 14–16].
The remaining studies used a composite reference stan-
dard that included histopathology and clinical follow-up.
Evaluation of study quality
The distribution of study quality according to the
QUADAS-2 tool is shown in Fig. 2. A risk of bias was
identified for all domains. Referring to Fig. 2 and Ta-
ble 2, most studies gave a clear description of partici-
pants, index and reference tests, and diagnostic criteria.
However, there were different study designs, and often
there was a composite standard of reference, which gave
rise to the most risk of bias. The risk of bias associated
with the Patient Selection domain was attributed to case–
control studies, which were defined as studies including
both patients with HCC and patients without HCC. Five
studies were ranked with high risk of bias due to a case–
control study design (n = 5) and/or a specified inclusion
criteria of patients, and two were ranked unclear due to
unclear study design (n = 2). All studies were carried out
blocking reference information from physicians when
they read the images, and all studies contain a clearly
pre-specified standard for imaging diagnosis, thus lead-
ing to a satisfactory risk of bias in index tests, resulting in
a satisfactory. The reference standard domain showed an
unclear risk of bias in all studies because of lack of
information on whether the pathological analysis was
blinded from the results of the index tests. The risk of
bias associated with the flow and timing domain was
primarily caused by the various reference standards,
meaning that not all patients were receiving a single type
of reference examination (n = 7).
Diagnostic accuracy
Results are presented in Table 3. The pooled sensitivities
of MRI and CT were, respectively, 0.86 (95% CI 0.76–
0.93) and 0.70 (95% CI 0.58–0.80). Likelihood ratio tests
showed that there is significant difference between the
pooled sensitivities of the two tests (P < 0.05). The
pooled specificities were shown to be similarly high, both
0.94 (95% CI 0.92–0.96) (P > 0.05). The summarized
PLR of both the tests were larger than 1.00, and the
summarized NLRs were smaller than 1.00, indicating
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informative results of both tests. The forest plots for
sensitivities and specificities of Gd-EOB-DTPA-en-
hanced MR imaging and multidetector CT are shown in
Fig. 3, and paired SROC curves for Gd-EOB-DTPA-
enhanced MR imaging and multidetector CT are shown
in Fig. 4. Paired SROC curves revealed the difference of
the diagnostic performance between the two studies: the
curve of MRI was formed above that of CT indicating a
seemingly larger area under the curve, which is related
with the diagnostic ability.
Subgroup analysis
Meta-regression analysis identiﬁed reference standard
(whether or not the ﬁndings of liver explantation were
used as the sole reference standard) as the most impor-
tant factor responsible for heterogeneity in the two tests;
therefore, subgroup analysis was performed based on
this factor. The results of subgroup analysis are shown in
Table 3. In all the subgroups, specificities of the two tests
maintained at a level similar with that of the overall
analysis, ranging from 0.91 to 0.95 with no significant
difference between them (P > 0.05). Sensitivities varied
among the subgroups, but the sensitivity of MRI was
higher than that of CT in all occasions with or without
statistical significance. The PLRs and NLRs remained
similar with the results of overall analysis. The forest
plots (Fig. 3) also showed subgroup analysis of paired
sensitivities and specificities of the two tests.
(a) Studies in which liver explant findings were used as the
sole reference standardwere included inone subgroup.
There were three studies in this subgroup [11, 14, 16].
The result was in accordance with overall diagnostic
performance, though the sensitivities of both the tests
were reduced: MRI 0.61 (95% CI 0.52–0.69) and CT
0.45 (95% CI 0.37–0.53). There was significant differ-
ence between the sensitivities (P < 0.05).
(b) The second subgroup included studies in which liver
explant findings were not the sole reference standard.
There were nine studies in this subgroup [7–10, 12,
Fig. 1. Flowchart illustrating the selection of studies.
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13, 15, 20, 21]. This time the sensitivity turned out to
be significantly higher than that of CT: 0.91 (95% CI
0.87–0.94) v.s. 0.76 (95% CI 0.64–0.84), P = 0.00.
This subgroup was further divided into two sub-
groups based on the inclusion of patients to further
break down possible heterogeneity. The first sub-
group included five studies in which all patients were
diagnosed with cirrhosis [7, 10, 13, 20, 21]. The sec-
ond subgroup included four studies in which only
partial patients had cirrhosis [8, 9, 12, 15]. Both of
the subgroups showed similar results as the subgroup
(b). The pooled sensitivities of MRI were, respec-
tively, 0.91 and 0.93 while those of CT, respectively,
0.74 and 0.77. Significant difference (P < 0.05) was
found in between the sensitivities of both tests in the
second subgroup where the inclusion had not been
confined to patients with cirrhosis. In the other
subgroup, there was limited difference (P = 0.05)
between the sensitivities of MRI and CT.
Lesion size
Size was proved to be an especially important factor for
the diagnostic performance of both tests (Table 4). Sen-
sitivities of MRI and CT were reduced as the size of
lesion reduced and were particularly low when the lesion
was less than 1 cm (MRI 0.46 (95%CI 0.30–0.63), CT
0.20 (95%CI 0.11–0.32)). But the sensitivity of MRI was
stably higher than that of CT in all sizes of lesions with
or without statistical significance (P < 0.05 in le-
sions £ 1 cm and lesions £ 2 cm, P > 0.05 in le-
sions > 1 cm and lesions > 2 cm).
Discussion
Although MR imaging and CT were compared in pre-
vious studies, such comparisons either did not conﬁne to
MR imaging with solely Gd-EOB-DTPA as contrast
agent, and included merely a limited number of head-to-
head comparison studies. Direct comparison is the
Fig. 2. Methodological
quality of the 20 included
studies assessed with
QUADAS-2 tools. A Risk of
bias; B concerns regarding
applicability.
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for the diagnosis of HCC by
Gd-EOB-DTPA Enhanced
MR imaging and
multidetector CT in each
study. The ‘‘Study’’ on the
left was illustrated in the
form of ‘‘first author/year/
sample size’’, ‘‘sample size’’
referring to the total number
of lesions detected in a
single study (please refer to
Table 2). A Overall analysis;
B Subgroup of studies using
findings in explanted liver as
the only reference; C
Subgroup in which findings
in explanted liver were not
used as the only reference;
D Further subgroup of
studies in which patients
were all diagnosed with
cirrhosis; E Further
subgroup of studies in which
patients were partially
diagnosed with cirrhosis.
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preferable method to analyze differences between two
techniques, as it reduces heterogeneity and provides
evidence at a higher level [22]. In addition, per-lesion
analysis provides additional information to that pro-
vided by per-patient analysis, such as the location of le-
sions. By searching literature thoroughly focusing on
studies of head-to-head comparison and by applying a
strictly designed inclusion criteria, we collected twelve
studies of quite a considerable number of patients and
lesions to perform this meta-analysis, aiming to add to
the evidence for the feasible application of either imaging
scan to detect HCC.
Summary of evidence
Our results revealed that in diagnosing HCC MR
imaging with Gd-EOB-DTPA showed similarly high
speciﬁcity of above 0.91 in both overall analysis and
subgroup analysis. Speciﬁcities of both tests maintained
at such a level steadily regardless of factors that could
inﬂuence diagnosis such as inclusion of patients or dis-
ease spectrum. And there was no signiﬁcant difference
between the speciﬁcities of the tests in all circumstances.
However, subgroup analysis based on lesion size was not
available for speciﬁcity due to lack of true-negative val-
ues. We suppose that size could have a substantial
inﬂuence on speciﬁcity, which should be considered in
future studies and clinical application.
Sensitivities of the two tests, different from speciﬁci-
ties, varied at multiple levels due to the change of disease
spectrum, disease severity, and lesion size. And signiﬁ-
cant difference was found between the sensitivities of
MRI and CT in many instances.
The overall sensitivities of MRI and CT were,
respectively, 0.86 and 0.70, suggesting that MRI is a
better choice to detect HCC. Subgroup analysis provided
further evidence.
When detecting HCC in patients who were diagnosed
with HCC by solely liver explant, sensitivities of both
MRI and CT were reduced to a great extent (MRI 0.61,
CT 0.45), probably due to the fact that patients who
underwent liver explant were those with more serious
hepatic conditions which could have diminished the
diagnostic performance of both tests. Even so, MRI was
signiﬁcantly more sensitive than CT in such cases. Al-
though the fact that only three studies satisﬁed such a
patient inclusion criterion should not be omitted, it still
suggested that MRI could be a better choice than CT to
detect HCC in patients with more serious liver diseases.
In the other subgroup where not all patients were
diagnosed by liver explant, sensitivities of both tests in-
creased, especially that of MRI. Additional subgroup
Fig. 4. Paired SROC curves of Gd-EOB-DTPA-enhanced
MR imaging (MRI) and multidetector CT (CT). A line connects
the pair of points representing the tests of MRI and CT from
each study.
Table 4. Sensitivity estimates for different lesion sizes
Lesion size Number of studies MRIa CTb Chi-square (dfd) P value
Sensitivity (95% CIc) Sensitivity (95% CI)
£1 cm 4e 0.46 (0.30–0.63) 0.20 (0.11–0.32) 4.62 (1) 0.03
>1 cm 6f 0.86 (0.73–0.94) 0.74 (0.56–0.87) 1.53 (1) 0.22
£2 cm 9g 0.82 (0.70–0.91) 0.53 (0.36–0.70) 6.41 (1) 0.01
>2 cm 3h 0.98 (0.85–1.00) 0.94 (0.71–0.99) 0.56 (1) 0.46
The studies were divided into subgroups based on the size of lesions. Sensitivity estimates were calculated for both imaging techniques and compared
in each subgroup
a Gd-EOB-DTPA-enhanced MR imaging
b Contrasted-enhanced multidetector CT
c Confidence interval
d Degrees of freedom
e Baek et al. [13], Kakihara et al. [14], Kim et al. [15], Yoo et al. [11]
f Baek et al. [13], Di Martino et al. [7], Granito et al. [20], Kakihara et al. [14], Kim et al. [15], Yoo et al. [11]
g Baek et al. [13], Di Martino et al. [7], Granito et al. [20], Haradome et al. [8], Kakihara et al. [14], Kim et al. [15], Park et al. [21], Sano et al. [9], Sun
et al. [10]
h Baek et al. [13], Granito et al. [20], Kim et al. [15]
J. Guo et al.: Diagnostic performance of contrast-enhanced multidetector computed tomography 1969
analysis based on whether or not all the included patients
had liver cirrhosis showed similar results. In this part of
subgroup analyses, the sensitivity of MRI stayed above
0.91, while the sensitivity of CT kept below 0.77.
Moreover, size affected the diagnostic performance of
both tests to a large extent. The lower diagnostic accu-
racy in small HCC lesions can be due to the fact that
small HCCs are usually early-stage and often lack the
characteristic features of HCC. Early HCCs are often not
hypervascular and are supplied mostly by portal venous
blood. Therefore, the routine imaging standard of in-
tense arterial uptake followed by a ‘‘washout’’ of con-
trast in the venous-delayed phases has limited
application in early HCCs [23]. Our results indicated that
HCC detection efficiency of MRI maintained at a higher
level than that of CT for detecting HCC lesions of all
sizes, especially those less than 1 cm (sensitivity estimate
of MRI versus that of CT: 0.46 versus 0.20) or even
larger sizes of less than 2 cm (sensitivity estimate of MRI
versus that of CT: 0.82 versus 0.53). Previous studies
showed that the sensitivity of MRI for detecting HCC
less than 1 cm was 0.46–0.48, whereas that of CT was
approximately 0.40 [24, 25]. For lesions smaller than
2 cm, sensitivity of MRI was approximately 0.62,
whereas that of CT was approximately 0.40 [25]. Our
results showed higher sensitivity of MRI for detecting
lesions less than 2 cm and better support the guideline of
AASLD in that lesions larger than 1 cm can be directly
diagnosed using non-invasive imaging modalities.
Comparison with previous literature
Although MR imaging and CT were compared in pre-
vious studies, a direct comparison of the per-lesion
diagnostic performance of Gd-EOB-DTPA-enhanced
MR imaging and multidetector CT for HCC had not
been performed to date. Therefore, we refer to previous
work focusing on the general comparison of MR imaging
and CT for HCC. A previous meta-analysis by Lee [24]
showed that MR imaging was more sensitive than mul-
tidetector CT for the diagnosis of HCC (80% vs. 68%),
and MR imaging with Gd-EOB-GDPA showed the
highest sensitivity (87%). Our results showed higher
sensitivity estimates for Gd-EOB-DTPA-enhanced MR
imaging. However, in that study, Gd-EOB-GDPA-en-
hanced MR imaging was not compared to multidetector
CT on a direct per-lesion basis. In a meta-analysis by
Chen et al. [26], the performance of MR imaging with
liver-specific contrast agents was superior to that of
multidetector CT (sensitivity: 0.91 vs. 0.81; specificity:
0.95 vs. 0.93), which is consistent with our results in the
subgroup analysis excluding studies that used liver ex-
plant findings as the sole reference. However, this re-
search included studies that used either Gd-EOB-DTPA
or superparamagnetic iron oxide particles as liver-speci-
fic contrast agents. The specific accuracy of Gd-EOB-
DTPA-enhanced MR imaging was not analyzed. Studies
have suggested that the effects of superparamagnetic iron
oxide particle enhanced MR imaging are not comparable
to those of Gd-EOB-DTPA-enhanced MR imaging [27].
At the same time, SPIO is not available worldwide since
it is not a contrast agent approved by United State Food
and Durg Administration, and therefore, its value of
application has been limited. [28]
Therefore, the analysis of the two contrast agents
together does not accurately reﬂect the performance of
Gd-EOB-DTPA-enhanced MR imaging. Furthermore,
this study was published as a postscript, and the
important details of the research, such as patient spec-
trum, imaging techniques, and reference standards, were
omitted. Our results were in agreement with those of
previous studies showing that MR imaging with liver-
speciﬁc agents is generally superior to CT for the diag-
nosis of HCC. Furthermore, our per-lesion and direct
comparison results support that MR imaging with Gd-
EOB-DTPA is superior to multidetector CT for the
detection of HCC. Direct comparison is the preferable
method to analyze differences between two techniques,
as it reduces heterogeneity and provides evidence at a
higher level [22]. In addition, per-lesion analysis provides
additional information to that provided by per-patient
analysis, such as the location of lesions.
Lesion size and comparison with previous
literature
Subgroup analysis in our study allowed the comparison
of the two imaging techniques in lesions of different sizes.
In accordance with previous studies, our results sug-
gested that size is a crucial factor in diagnosing HCC.
Previous studies showed that for lesions smaller than
1 cm, sensitivity estimate of Gd-EOB-DTPA-enhanced
MR imaging was approximately 0.46–0.48, whereas that
of CT was approximately 0.40 [24, 25]. For lesions
smaller than 2 cm, sensitivity estimate of Gd-EOB-
DTPA-enhanced MR imaging was approximately 0.62,
whereas that of CT was approximately 0.40 [25]. Our
study showed similar sensitivity for lesions smaller than
1 cm (0.46), whereas sensitivity was higher for lesions
smaller than 2 cm (0.82) compared with these previous
results. The lower diagnostic accuracy in small HCC le-
sions is due to the fact that small HCCs are usually early-
stage and often lack the characteristic features of HCC.
Early HCCs are often not hypervascular and are sup-
plied mostly by portal venous blood. Therefore, the
routine imaging standard of intense arterial uptake fol-
lowed by a ‘‘washout’’ of contrast in the venous-delayed
phases has limited application in early HCCs [23].
According to the AASLD, lesions smaller than 1 cm
should be controlled by ultrasound surveillance, whereas
those larger than 1 cm can be directly diagnosed using
non-invasive imaging modalities. Therefore, it is crucial
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to improve the diagnostic performance for HCC lesions
smaller than 1 cm. Our results indicated that for smaller
HCC lesions, especially for those smaller than 1 cm, the
sensitivity of MR imaging with Gd-EOB-DTPA was
higher than that of multidetector CT.
Summary and limitations
Overall, compared with previous studies, our results
provided the ﬁrst meta-analytical direct per-lesion com-
parison evidence that Gd-EOB-DTPA-enhanced MR
imaging was more suitable for diagnosing HCC than
multidetector CT. The superiority of Gd-EOB-DTPA-
enhanced MR imaging could be attributed to the fact
that MR imaging with Gd-EOB-DTPA detects HCCs
using a combination of the above multiphasic standard
and the enhancement pattern during HBP. Gd-EOB-
DTPA is a liver-speciﬁc agent that is taken up by hepa-
tocytes. It entry into hepatocytes is mediated by organic
anion transporting polypeptides OATP1B1/B3, and its
excretion into the bile occurs via the multidrug resistance
protein 2 (MRP2). During HBP, most HCCs appear
hypointense because OATP1B1/B3 is downregulated and
MRP2 is upregulated [6]. Therefore, in hypovascular
early HCCs, HBP may assist diagnosis as it does not
depend on the vascular pattern.
Our study had several limitations. First, the studies
we analyzed included a relatively broad spectrum of
patients, including patients suspected of HCC, patients
with FLLs, and patients who had previously undergone
treatment for HCC. This could lead to bias in patient
selection and inﬂuence the diagnostic results, as different
diagnostic criteria and thresholds are adopted for various
populations. Second, a composite reference standard was
used in the studies included in the current work,
including histopathology and clinical follow-up. How-
ever, this might better represent the daily clinical prac-
tice. Third, the diagnostic criteria for HCC using MR
imaging with Gd-EOB-DTPA varied among the included
studies in our work from typical dynamic appearance to
a combination of part of the typical dynamic appearance
(e.g., only ‘‘washout’’ without intense arterial intake) and
HBP hypointensity or HBP hypointensity alone. How-
ever, during HBP, 5%–10% of HCCs are iso- or hyper-
intense relative to the liver because of low or high MRP2
expression [29]. Therefore, the diagnostic performance of
HBP hypointensity needs further investigation. Fourth,
the imaging technique also varied among the included
studies that we analyzed. For example, timing of the
delayed phase ranged from 120 to 180 s for Gd-EOB-
DTPA-enhanced MR imaging and from 150 to 240 s for
CT imaging. This could lead to bias in index tests. Based
on the above considerations, we would evaluate the
overall study quality in the current research to be med-
ium–high according to a relatively concordant selection
of patients, well-designed index tests, acceptable variety
of reference standards, and considerate set of index
evaluation timing in most studies. Fifth, specificity sub-
group analysis failed to carry out due to lack of true-
negative values. However, size may have a considerable
influence on specificity too. Sixth, papers written in an-
other language generally merely provided an English
abstract instead of a full English version and required the
relative language ability which unfortunately we do not
have. Therefore, the current study only included papers
written in English, to avoid risk caused by wrong inter-
pretation of the study and a single opinion due to the
language of a co-worker. Future studies should take this
into consideration and include as much variety of studies
as possible to contribute to the evidence.
Conclusion
MR imaging with Gd-EOB-DTPA is superior to multi-
detector CT for the diagnosis of HCC, showing higher
sensitivity in more demanding situations such as severe
cirrhosis or lesions measuring smaller than 1 cm.
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